Haystack Oncology

Haystack Oncology was acquired by Quest Diagnostics in 2023. Haystack Oncology evaluates circulating tumor DNA with ultrasensitive next-generation sequencing to identify residual, recurrent, and resistant disease in cancer patients, providing best-in-class personalized testing that prompts proactive clinical interventions to dramatically improve patient outcomes.